Economic Observation Network We plan to submit a new drug application for ALXN1840 to treat Wilson's disease to the US FDA in the near future. The relevant clinical data has been released, and the stock price has reached a 52 week high.

Product development progress:
The company plans to submit a New Drug Application (NDA) for ALXN1840 in the treatment of Wilson's disease to the US FDA in mid-2026 (i.e. in the near future) This is the most crucial step for the company to move from the clinical stage to commercialization, and its submission time, subsequent FDA acceptance, and review schedule will directly affect the stock price.

At the end of June 2026, the company announced new analysis data from the Phase 3 FoCus study at the European Congress of Neurology, which showed that ALXN1840 was significantly superior to standard therapy in terms of neurological function improvement and overall clinical evaluation, providing strong support for NDA 。

Recent stock trends:
Driven by this progress, the company's stock price reached a 52 week high in early July 。

The above content is based on publicly available information and does not constitute investment advice.